Neuronal network formation in the developing nervous system is dependent on the accurate navigation of nerve cell axons and dendrites, which is controlled by attractive and repulsive guidance cues. Ephrins and their cognate Eph receptors mediate many repulsive axonal guidance decisions by intercellular interactions resulting in growth cone collapse and axon retraction of the Eph-presenting neuron. We show that the Rac-specific GTPase-activating protein a2-chimaerin binds activated EphA4 and mediates EphA4-triggered axonal growth cone collapse. a-Chimaerin mutant mice display a phenotype similar to that of EphA4 mutant mice, including aberrant midline axon guidance and defective spinal cord central pattern generator activity. Our results reveal an achimaerin-dependent signaling pathway downstream of EphA4, which is essential for axon guidance decisions and neuronal circuit formation in vivo.
INTRODUCTION
Many axonal guidance processes that take place during neuronal network formation in mammals are regulated by the ephrin/Eph system. Ephrins are surface-associated ligands that bind to Eph receptors, which constitute the largest family of receptor tyrosine kinases. This interaction triggers intracellular signaling pathways in the contacting nerve cells and typically causes the collapse of Eph-presenting growth cones and axon repulsion. Eph receptor signaling during axon guidance is initiated by a multistep process that involves ephrin binding, activation of the tyrosine kinase activity, autophosphorylation, and higher-order clustering. Eph receptor complexes activated in this manner signal to Rho family GTPases to trigger cell-cell detachment and reorganization of the actin cytoskeleton, which ultimately results in growth cone collapse and axon retraction (Egea and Klein, 2007) . The current knowledge about intracellular signaling proteins that transduce Eph receptor signals to Rho family GTPases is fragmentary. In fact, the only identified RhoGTPase regulators that act downstream of activated Eph receptors are guanine nucleotide exchange factors (RhoGEFs), of which the best characterized are members of the ephexin and Vav families Cowan et al., 2005) . Whether and how their activity is counterbalanced and complemented by Eph-dependent Rho/Rac inhibitors such as RhoGTPase-activating proteins (RhoGAPs) is unknown.
Members of the chimaerin family of Rac-specific GAPs are candidate regulators of the outgrowth and pathfinding of neuronal axons and dendrites. The mouse genome contains two chimaerin genes (a-chimaerin, chn1; b-chimaerin, chn2), each of which gives rise to the expression of two isoforms, a1/a2 and b1/b2. All chimaerins contain a RacGAP domain and a regulatory diacylglycerol-binding C1 domain, while only a2-and b2-chimaerin contain an additional SH2 domain at their N termini (Yang and Kazanietz, 2003) . Mammalian a2-chimaerin, which is mainly expressed in the embryonic nervous system, is thought to be involved in semaphorin3A-induced growth cone collapse of rat dorsal root ganglion neurons (Brown et al., 2004) . In zebrafish, a2-chimaerin appears to be required for morphogenic movements during early development . Mammalian a1-chimaerin, on the other hand, is mainly expressed postnatally and is involved in the pruning of dendritic spines and branches of hippocampal neurons (Van de Ven et al., 2005; Buttery et al., 2006) . These functions are dependent on the RacGAP domains of a1-and a2-chimaerin and were shown to require C1 domain ligand binding (Brown et al., 2004 ; Van de Ven et al., 2005; Buttery et al., 2006) .
In the present study, we used biochemical and mouse genetic tools to examine the role of a2-chimaerin in vivo. Our data show that a2-chimaerin is a downstream effector of activated EphA4 and is essential for EphA4-dependent axon navigation during neuronal network formation in the mouse brain and spinal cord. a2-Chimaerin binds to and is phosphorylated by EphA4, and deletion of a2-chimaerin in mutant mice causes deficient Eph-mediated growth cone collapse in cortical and spinal cord neurons. The resulting mutant phenotype thus mimics that of mouse mutants with deficient EphA4-dependent forward signaling. It is characterized by aberrant wiring of neuronal networks that control coordinated limb movements, which in turn causes an unusual hopping gait.
RESULTS

Chimaerins Interact with Eph Receptors
To identify interactors of the a2-chimaerin SH2 domain that trigger or regulate a2-chimaerin signaling to Rac, we performed a modified yeast two-hybrid (YTH) screen using a rat brain cDNA prey library together with a fusion protein of the a2-chimaerin SH2 domain and the Src kinase domain as bait. Under these conditions, the Src kinase domain can phosphorylate tyrosine residues of prey proteins, a posttranslational modification that is typically required for SH2 domain interactions but would otherwise not take place in yeast (Park and Yun, 2001 ). We isolated multiple identical prey clones encoding the kinase domain (residues 632-902) of EphB1 as interactors of the a2-chimaerin SH2 domain. To test whether this interaction is a common feature of chimaerins and extends to other Eph receptors, we studied interactions of a2-chimaerin-SH2-src-kinase and b2-chimaerin-SH2-src-kinase fusion constructs with the kinase domains of EphB1 and EphA4 (residues 634-902) in YTH assays. The SH2-src-kinase fusion proteins of a2-and b2-chimaerin bound to the kinase domains of EphB1 and EphA4 while the isolated SH2 or Src kinase domains did not or only very weakly (Figure 1 ), indicating that the interaction is phosphorylation dependent and common to all chimaerin SH2 domains and multiple Eph receptors.
Similar Phenotypic Changes after Genetic Perturbation of a-Chimaerin or EphA4 Function
To analyze the function of a-chimaerins in vivo, we generated knockout mice (a-chimaerin
) lacking a-chimaerin expression entirely and knockin mice (a-chimaerin mut/mut ) with a point mutation of the first histidine in the C1 domain (H81K and H206K in a1-and a2-chimaerin, respectively; see Figure S1 in the Supplemental Data available with this article online). The knockin was intended to result in the expression of diacylglycerol (DAG)-insensitive a-chimaerin proteins, but instead caused a complete loss of wild-type a1-chimaerin expression and expression of an aberrantly spliced a2-chimaerin transcript. This led to a 26 residue deletion in the a2-chimaerin protein (D184-209) and a 95% reduction of total a2-chimaerin protein expression ( Figure S2 ).
Heterozygous animals of both mutant lines lacked any obvious phenotypic changes. Similarly, newborn homozygous mutants of both lines were viable and indistinguishable from wild-type (WT) and heterozygous littermates. Shortly after birth, both a-chimaerin mutant lines displayed smaller body sizes but in most cases acquired normal body size until early adulthood. With the onset of locomotion, a rabbit-like hopping gait was apparent in achimaerin À/À and a-chimaerin mut/mut mice. Instead of a normal alternating gait, these animals moved first their forelimbs in parallel and then their hindlimbs in parallel (Figures 2A-2C ). In addition, homozygous mutants of both lines exhibited tonic seizures, and a-chimaerin À/À mice showed a tendency for rightward circular locomotion. Analyses of the brain morphology of a-chimaerin mouse mutants revealed enlarged ventricles in some achimaerin mut/mut and all a-chimaerin À/À mice but no other obvious changes in the cytoarchitecture of the brain, including the anterior commissure (AC) ( Figure S3 ).
a-Chimaerin mutant mice display a hopping gait similar to EphA4 À/À mice (Dottori et al., 1998) , ephrinB3 À/À mice (Yokoyama et al., 2001; Kullander et al., 2001a) , and knockin mice expressing EphA4 variants with defective forward signaling (Kullander et al., 2001b; Grunwald et al., 2004; Egea et al., 2005) . Our YTH studies indicated a functional involvement of a2-chimaerin in EphA4 forward signaling. EphA4 À/À mice and several EphA4 mutants with defective forward signaling show perturbations of spinal cord architecture due to aberrant axon guidance decisions of mutant neurons (Dottori et al., 1998; Kullander et al., 2001b) . Such changes were also seen in a-chimaerin mutant mice. Their dorsal funiculi, which contain axons of the corticospinal tract (CST) originating from neurons in the motor cortex, were broader ( Figures 2D-2G) , and the axons of the CST, which represents an important pathway in the regulation of voluntary distal limb movements, aberrantly recrossed the spinal cord midline ( Figures 2H-2K) . Most of the defects seen in the a-chimaerin mutants were more severe in a-chimaerin À/À than in a-chimaerin mut/mut mice, indicating that the remaining aberrantly spliced a2-chimaerin-D184-209 is still partially active. Elimination of EphA4 forward signaling in the mouse also results in a dysfunction of the central pattern generator (CPG) for hindlimb movement (Kullander et al., 2003) , an oscillatory neuronal network that generates rhythmic activities and thus patterns muscle contractions. EphA4-positive neurons are a major component of ipsilaterally projecting excitatory interneurons, which are likely part of the locomotor CPG. In addition, the locomotor CPG contains ipsilaterally projecting inhibitory interneurons, which coordinate flexor-extensor activities, and inhibitory and excitatory commissural interneurons (CINs), which cross the ventral spinal cord midline to reciprocally control the activity of contralateral motor neurons and hence coordinate left-right activities (Kiehn, 2006) . We recorded the activity of the locomotor CPG electrophysiologically using isolated spinal cords from a-chimaerin À/À mice and WT littermates. Recordings from WT mice showed alternating left-right ventral root activities, which account for alternating left-right limb movements ( Figures 3A-3C ). In contrast, the left-right firing pattern of the ventral roots in lumbar segment 2 (lL2-rL2) of a-chimaerin À/À animals was rather uncoordinated and switched between asynchronous and synchronous activities, whereas ipsilateral intersegmental flexor-extensor (lL2-lL5) activities were normal ( Figures 3D-3F ). This phenotype is reminiscent of the consequences of defective EphA4 signaling, which results in the synchronization of left-right hindlimb motor activities, most likely due to axons of excitatory interneurons that aberrantly cross the midline of the ventral spinal cord (Kullander et al., 2003; Butt et al., 2005) .
To examine whether the uncoordinated left-right spinal ventral root activities observed in the a-chimaerin À/À mice are due to a defect in the distribution of CINs, we applied tracer substances to one side of lumbar segments of WT and a-chimaerin À/À spinal cords to visualize CINs and their processes. a-Chimaerin À/À mice showed fibers that aberrantly crossed over the midline dorsally and ventrally of the central canal, while no obvious defects in the position and number of CINs were detectable (Figures 3G-3X and Figure S6 ). These defects are similar to the defects observed in EphA4 À/À mice (Kullander et al., 2003) .
Taken together, the interaction between a2-chimaerin and Eph receptors and the similar phenotypic consequences of a-chimaerin mutations and perturbed EphA4 forward signaling show that a-chimaerins are downstream effectors of ephrin-triggered forward signaling through Eph receptors. a2-Chimaerin exhibits high expression levels in the rat embryonic nervous system, while the expression of a1-chimaerin essentially commences after birth (Hall et al., 2001) . Among other regions, a2-chimaerin mRNA is detected in the cortex and in the spinal cord of rat embryos. In particular, at E12.5, a2-chimaerin mRNA is expressed at high levels in the spinal cord mantle layer, especially in differentiating motor neurons of the ventral horn. By E16.5, an increased expression can be detected in the cortical plate, from which the corticospinal tract axons arise (Hall et al., 2001) . This expression pattern is coincident with the EphA4 expression in the spinal cord and the cortical plate (Kullander et al., 2001b; Greferath et al., 2002) . We compared the expression of a2-chimaerin and EphA4 by in situ hybridizations in the mouse spinal cord (E15.5 and P0) as well as motor cortex (E18.5 and P0) and found both mRNAs to be expressed in the same neuronal populations. We specifically studied the motor cortex in these in situ hybridization experiments because we used the neurons from this region for growth cone collapse and tracing experiments. a2-Chimaerin showed a widespread expression throughout the gray matter in spinal cord segments analyzed, covering the expression domain of EphA4 mRNA. In the motor cortex, both EphA4 and a2-chimaerin were expressed in the cortical plate and the ventricular and subventricular zones ( Figure S4 ). These data show that a2-chimaerin is spatially and temporally expressed in the same regions of the spinal cord and motor cortex as EphA4 and may explain the similar defects observed in CSTs and spinal cords of EphA4 À/À and a-chimaerin À/À mice.
a-Chimaerins Are Components of EphA Receptor Forward Signaling Pathways CST axons project from neurons located in the motor cortex. Therefore, we used dissociated neuron cultures of E16.5 motor cortices from a-chimaerin mutants and WT littermates in order to directly address the involvement of a-chimaerins in Eph forward signaling. We stimulated the neurons with either ephrinB3 or ephrinA1 and counted the number of collapsed growth cones. In these cultures, ephrinB3 is a specific ligand for EphA4, whereas ephrinA1 activates additional EphA receptor subtypes. Cortical neurons from knockin mice with disrupted EphA4 forward signaling no longer respond to ephrinB3 but are still responsive to ephrinA1 (Egea et al., 2005) . In cultures of a-chimaerin mut/mut and a-chimaerin À/À neurons, the numbers of collapsed growth cones were significantly reduced after stimulation with either ephrinB3 or ephrinA1 (Figure 4) . This was not caused by loss of EphA4 expression and/or activity, because the amount of EphA4 protein in WT and a-chimaerin À/À neurons as well as the degree of EphA4 phosphorylation after ephrinA1 stimulation were unchanged ( Figure 4D ). These findings show that EphA4 and likely also other Eph receptors use a-chimaerins for forward signaling. We next analyzed how EphA4 regulates a2-chimaerin. We used full-length WT EphA4 (EphA4 WT) or mutant EphA4 with an inactive kinase domain (EphA4 KD) , and a-chimaerin À/À E16.5 embryos were kept in culture for 36 hr, then stimulated for 30 min with 2 mg/ml of preclustered Fc (A and B), ephrinB3 (A), or ephrinA1 (B), fixed, stained with phalloidin, and scored for collapsed or uncollapsed growth cones. In each experiment, the average SEM of the percentage of collapsed growth cones from three to five coverslips (80-100 growth cones per coverslip) was plotted. **p < 0,01; ***p < 0,001 (Student's t test).
(C) Representative examples of scored phalloidin-stained neurons. Neurons with an unaffected growth cone (GC) with strong actin staining (arrow) were considered as uncollapsed, whereas neurons were scored as collapsed when reduced actin staining was observed and no filopodial extensions at the tip of the axon could be detected (arrowheads (Kullander et al., 2001a) expressed in 293FT cells and studied their binding to bacterially expressed GST-tagged a-chimaerin constructs. We followed this experimental strategy because immunoprecipitation of either EphA4 or a-chimaerins from brain extracts or coexpressing cultured cells did not result in the coprecipitation of the corresponding binding partner. Full-length a2-chimaerin interacted with EphA4 WT and to a lesser extent with EphA4 KD. The same was true for an N-terminal a2-chimaerin fragment containing the SH2 domain (residues 1-183), while a corresponding mutant fragment with a phosphotyrosine-binding-deficient SH2 domain (residues 1-183, R73L) bound only very weakly to EphA4 WT and EphA4 KD ( Figure 5A) . Surprisingly, also a1-chimaerin, which has a completely unrelated N terminus without an SH2 domain, bound equally strongly to EphA4 WT and EphA4 KD, indicating an interaction that is independent of a functional kinase domain ( Figure 5A ). An a2-chimaerin variant lacking its SH2 domain bound more strongly to EphA4 WT than to EphA4 KD ( Figure S5A ), demonstrating that the SH2 domain is not the only EphA4 binding site in a2-chimaerin. However, a conserved binding site in a-chimaerins for EphA4 would not explain the phosphorylation independence of the a1-chimaerin-EphA4 interaction, which rather reflects a specific binding site for a1-chimaerin in EphA4.
To determine whether EphA4 provides a second binding site for a-chimaerins outside its kinase domain, we tested whether a-chimaerins can bind to the juxtamembrane (JM) region of EphA4 as well. We used two different (A and B) , and GST-a2-chimaerin proteins but not GST-a1-chimaerin bind to Nck1 and Nck2 in cosedimentation experiments (C). Indicated EphA4 and Nck proteins were expressed in 293FT cells and used in cosedimentation experiments with bacterially expressed GST-tagged a-chimaerin fusion proteins. GST, glutathione S-transferase; GST-chim, GST-tagged a-chimaerin proteins; a1, a1-chimaerin; a2, a2-chimaerin; a2-1-183 WT, a2-chimaerin 1-183; a2-1-183 R73L, ; pTyr, phosphotyrosine; Lysate, 293FT cell lysate containing heterologously expressed proteins; WB, western blot. (D-F) a-Chimaerin proteins undergo EphA4-dependent phosphorylation. Indicated myc-tagged a-chimaerin and untagged EphA4 proteins were coexpressed in 293FT cells, and a-chimaerin proteins were immunoprecipitated (D and E). Cultured cortical neurons from P0 mice were infected 2 hr after plating with recombinant lentiviruses leading to the expression of EGFP-a2-chimaerin. At DIV5 these neurons were either control stimulated with preclustered Fc or stimulated with preclusterd Fc-ephrinA1 (5 mg/ml each) for the indicated times (F). Myc-chim, myc-tagged a-chimaerin proteins; a2, a2-chimaerin; a1, a1-chimaerin; a2-R73L, a2-chimaerin 
EphA4 mutants, EphA4
EE and EphA4 FF , where the two tyrosine residues in the JM region (Y596, Y602), which normally are autophosphorylated upon EphA4 activation, are replaced by glutamic acid and phenylalanine residues, respectively. These mutants lack the ability to bind to SH2 domains (Zisch et al., 2000; Binns et al., 2000; Cowan et al., 2005) . We found that the efficient binding of fulllength a-chimaerins to EphA4 does not seem to require its JM tyrosines, as both a1-and a2-chimaerin interacted equally well with EphA4 WT, EphA4 EE , and EphA4 FF ( Figure 5B ). However, we cannot exclude the possibility that JM tyrosines in EphA4 contribute to a-chimaerin binding in a way that evaded detection with our assay system. In addition, the binding of both a-chimaerin variants to an EphA4 mutant lacking its C-terminal SAM and PDZ binding domains was unaffected by the EphA4 mutation (data not shown). These data confirm our initial finding from YTH assays in which the kinase domain of EphA4 is sufficient to mediate the binding to a2-chimaerin and indicate the presence of a binding site for a1-chimaerin in the EphA4 kinase domain as well. Some downstream effectors of activated EphA4 are phosphorylated in an EphA4-dependent manner (Murai and Pasquale, 2005) . To test whether a1-and a2-chimaerin are tyrosine phosphorylated in an EphA4-dependent manner, we coexpressed them with either EphA4 WT or EphA4 KD in 293FT cells and analyzed their phosphorylation status after immunoprecipitation by western blotting. Full-length a1-and a2-chimaerin were tyrosine phosphorylated in the presence of EphA4 WT but not in the presence of EphA4 KD or in the absence of EphA4 ( Figure 5D ). a2-Chimaerin R73L was also tyrosine phosphorylated upon coexpression with EphA4 WT, albeit to a lesser extent than WT a2-chimaerin ( Figure 5E ). To test for tyrosine phosphorylation of a2-chimaerin by neuronal EphA4, we expressed EGFP-a2-chimaerin in cortical cultures and analyzed its phosphorylation after ephrinA1 stimulation. We found that a2-chimaerin was phosphorylated on tyrosine residues after stimulation of endogenous EphA receptors ( Figure 5F ).
In an attempt to identify tyrosine phosphorylated residues in a-chimaerins, we first mutated several tyrosines in the conserved C terminus and studied the phosphorylation of these mutants. Based on reduced phosphorylation levels in the corresponding mutants, we identified Y202, Y303, and Y333 of a2-chimaerin as putative phosphorylation sites ( Figure 5E ). In addition to the conserved C terminus, the N terminus (residues 1-200) of a2-chimaerin was also analyzed and found to be phosphorylated in an EphA4-dependent manner ( Figure S5D ). These data show that a-chimaerins contain multiple tyrosine phosphorylation sites.
The above data show that intact full-length a2-chimaerin binds to the kinase domain of EphA4 primarily when EphA4 is activated, i.e., tyrosine phosphorylated, while a1-chimaerin binds EphA4 in a constitutive manner. The a2-chimaerin-EphA4 interaction is mediated by the SH2 domain of a2-chimaerin and an additional binding site. Both, a1-and a2-chimaerin are tyrosine phosphorylated in an EphA4-dependent manner. Apparently, this is not required for EphA4 binding in experiments with bacterially expressed proteins, where unphosphorylated a-chimaerin proteins interacted with EphA4.
The Eph Adaptors Nck1 and Nck2 Bind to a2-and b2-Chimaerin Nck1 and Nck2 (Grb4) are adaptor proteins with one SH2 domain and three SH3 domains that interact with Eph receptors (Holland et al., 1997; Stein et al., 1998; Bisson et al., 2007) . a2-Chimaerin was recently shown to bind Nck1 (Wells et al., 2006) . WT full-length a2-chimaerin, but not a1-chimaerin, bound to Nck1 and Nck2 ( Figure 5C ). The interaction requires the SH2 domain of a2-chimaerin and is unaffected by the R73L mutation ( Figure 5C and Figure S5C ). Additionally, a GST-Nck1 fusion protein lacking its SH2 domain bound to full-length a2-chimaerin ( Figure S5B ). These data indicate that a2-chimaerin and Nck form a stable complex involving the chimaerin SH2 domain and one of the Nck SH3 domains.
Regulation of the RacGAP Activity of a-Chimaerins
We next examined the consequences of EphA4 and Nck binding for the RacGAP activity of a-chimaerins. We expressed a-chimaerins in the presence or absence of EphA4 and Nck2 in 293FT cells and measured the GTP load of endogenous Rac in pull-down assays. In the absence of EphA4, WT a1-and a2-chimaerin exhibited similar RacGAP activities, causing similar reductions in RacGTP levels ( Figure 6 , bars 7 versus 1 and 11 versus 1).
To analyze the influence of the C1 domain on the RacGAP activity of a2-chimaerin, we used its H206K mutant variant in the same assay. Structural data on b2-chimaerin showed that the molecule in its inactive state is kept in a closed conformation by intramolecular interactions of several regions with the C1 domain. In this conformation, the N terminus protrudes into the RacGAP domain, thereby blocking Rac binding (Canagarajah et al., 2004) . Based on these data, it was predicted that DAG and phospholipid binding to the C1 domain causes translocation of b2-chimaerin to the plasma membrane and unfolding of the protein, which exposes its RacGAP domain and thereby increases RacGAP activity (Canagarajah et al., 2004) . Indeed, b2-chimaerin exhibits an increased RacGAP activity in RacGTP pull-down assays when stimulated with the phorbol ester PMA, a functional analog of DAG (Caloca et al., 2003) . In COS cells, the induction of EGF receptor signaling with subsequent DAG production by phospholipase Cg (PLCg) causes b2-chimaerin to translocate to the plasma membrane where it binds to Rac1. In the same study, RNAi knock down of endogenous b2-chimaerin in HEK293 cells resulted in a sustained Rac activity after EGF stimulation . Similar C1-domain-mediated effects were reported for a2-chimaerin. When expressed in neuroblastoma cells, a2-chimaerin translocates to cell membranes, reduces endogenous RacGTP levels, and promotes neurite retraction after PMA treatment (Brown et al., 2004) . The authors postulated that a2-chimaerin exists in an autoinhibited conformation in the cytosol (Brown et al., 2004) . Because of the high similarity of a2-and b2-chimaerin in terms of their primary amino acid sequence and spatial distribution of structural domains within the molecules, we hypothesized that inactive a2-chimaerin is folded in a closed conformation similar to the structure described for inactive b2-chimaerin (Canagarajah et al., 2004) . To mimic the unfolding of the protein that is naturally induced by DAG and phospholipid binding, we mutated the invariant first histidine of the a2-chimaerin C1 domain (H206K). Although this mutation abolishes DAG binding by destruction of the C1 domain secondary structure (Quest et al., 1994; Rhee et al., 2002) , we expected that the autoinhibitory intramolecular interactions within a2-chimaerin would be abrogated as well, rendering its tertiary structure an open conformation. Indeed, the C1 domain mutant a2-chimaerin H206K showed a robust increase in RacGAP activity ( Figure 6 , bars 5 versus 7), causing further reductions in RacGTP levels as compared to WT a2-chimaerin. The coexpression of EphA4 did not change the basal RacGAP activities of a1-and WT a2-chimaerin (Figure 6 , bars 11 versus 12 and 7 versus 8). Similarly, influence of Nck2 on the RacGAP activity of WT a2-chimaerin was negligible ( Figure 6 , bars 9 versus 7), and Nck2 did not influence the activity of a1-chimaerin (Figure 6 , bars 13 versus 11) nor did it change basal cellular RacGTP levels when expressed alone ( Figure 6, bars 15 versus 1) . When Nck2 and EphA4 were coexpressed in the absence or presence of a2-chimaerin, increases in RacGTP levels were observed ( Figure 6 , bars 16 versus 15 and 10 versus 8). On the other hand, the enhancement of Rac activity upon Nck2/EphA4 expression was completely reverted by the presence of a1-chimaerin ( Figure 6 , bars 16 versus 14), which does not interact with Nck2 ( Figure 5C and Figure S5C ).
With the limitations of this assay, which does not yield equal expression levels of all three proteins tested, we could not clarify the consequences of a concerted EphA4/a2-chimaerin/Nck2 action on Rac. Three explanations of the data set are plausible: (1) in the presence of activated EphA4, Nck2 both inhibits the RacGAP activity of a2-chimaerin and increases the GTP load of Rac; (2) a2-chimaerin and EphA4-activated Nck2 regulate Rac activity in an antagonistic manner; (3) a2-chimaerin and Nck2 balance the activity of Rac in a cooperative and EphA4-dependent manner. However, with this assay we found that full RacGAP activity of a2-chimaerin seems to depend on the unfolding of its tertiary structure. This cannot be mediated by EphA4 and/or Nck binding or by tyrosine phosphorylation, but it may occur in response to additional DAG binding to the C1 domain of a2-chimaerin, which can be triggered by EphA4-dependent activation of phospholipase Cg1 (Zhou et al., 2007) .
DISCUSSION
The present study identifies the RacGAP a-chimaerin as an essential component of the EphA4 receptor signaling pathway that mediates axon guidance and growth cone collapse. This conclusion is supported by five complementary lines of evidence: (1) both a1-and a2-chimaerin interact with EphA4 and are phosphorylated in an EphA4-dependent manner; (2) a-chimaerin-deficient cortical neurons show a partially inhibited growth cone collapse response to ephrins; (3) a-chimaerin mutant mice exhibit developmental abnormalities that are observed in EphA4 mutants with defective forward signaling, including broadened dorsal funiculi in the spinal cord and abnormal midline recrossing of CST axons; (4) like ephrinB3
, and various EphA4 mutant lines with perturbed EphA4 receptor forward signaling, deletion of a-chimaerins in mice causes an abnormal rabbit-like hopping gait, probably caused by the observed abnormal midline crossing of axons in the lumbar spinal cord that participate in the hindlimb motor CPG; (5) like in EphA4 À/À and ephrinB3 À/À mice, the electrophysiological activity of the CPG for hindlimb locomotion is defective in achimaerin À/À mice. Given that the CST and neuronal networks in the spinal cord develop rather early in mice, the phenotypes we observed here are most likely due to a2-chimaerin loss because it is most strongly expressed during embryonic development when a1-chimaerin expression is low (Hall et al., 2001) . The observation that ephrinB3-mediated growth cone collapse is deficient in the absence of a2-chimaerin (Figure 4 ) directly links a2-chimaerin function to Eph receptor forward signaling and indicates that the phenotypic changes described above are mostly due to misled axon guidance decisions of EphA4-presenting growth cones lacking a2-chimaerin during early network formation. Because a1-chimaerin expression is low in embryonic stages and increases postnatally, its interaction with EphA4 is most likely relevant at later stages of brain development and in the adult brain. Possible functions may include the pruning of spines and dendrites or Eph-mediated synaptic plasticity (Yamaguchi and Pasquale, 2004; Grunwald et al., 2004) , but additional studies are required to test this hypothesis in detail.
Several lines of evidence indicate that a2-chimaerin may act downstream of multiple Eph receptors. Our initial YTH screen demonstrated that a2-chimaerin binds EphB1 (Figure 1 ), and our growth cone collapse assays showed that a2-chimaerin loss interferes with ephrinB3-and ephrinA1-induced growth cone collapse (Figure 4) . Further support is provided by the observation that achimaerin À/À mice display a stronger phenotypic change with severely desynchronized left-right ventral root activities as compared to EphA4 À/À mice, which show a shift from alternating to synchronized left-right ventral root activities of the hindlimb locomotor CPG. This finding may reflect additional mistargeting of CIN projections within the CPG of a2-chimaerin À/À mice. EphA2 and some EphB receptors are expressed by CINs (Imondi et al., 2000; Brittis et al., 2002) , and the EphB1/2/3 triple knockout exhibits CIN projections that follow an incorrect path on the contralateral side of the spinal cord (Kadison et al., 2006) . a2-Chimaerin may be involved in the pathfinding of growth cones presenting Eph receptors other than EphA4, and subtle mistargeting of CIN projections, which may have evaded detection in our tracing analysis, may contribute to the severe phenotypic changes seen in the CPG of a-chimaerin À/À mice. Similarly, a2-chimaerin may also act in semaphorin-mediated guidance of CIN projections, as it was shown to be involved in the Sema3A-induced growth cone collapses of DRG neurons (Brown et al., 2004) . Given that EphA4 functionally interacts with a2-chimaerin but does not alter its RacGAP activity, our data are best compatible with a role of a2-chimaerin in controlling Rac activity at the site of activated EphA4. Here, a2-chimaerin may either locally exert its basal RacGAP activity or experience additional activation through DAG binding to its C1 domain, resulting in a stronger but spatially confined downregulation of Rac. However, the production of DAG by PLCs in the ephrin-Eph-mediated signaling steps that lead to growth cone collapse has not been demonstrated yet. Furthermore, a2-chimaerin and Nck may control the activity of Rac in concert, causing a balanced activation of Rac. Indeed, Rac undergoes bidirectional activity changes during ephrin-induced growth cone collapse. After cell-cell contact via ephrin-Eph binding, Rac activity initially decreases, but is quickly restored (Wahl et al., 2000; Jurney et al., 2002) .
Restored Rac activity results in receptor-ligand internalization, which terminates cell-cell contact and is essential for growth cone retraction (Jurney et al., 2002; Zimmer et al., 2003; Marston et al., 2003) . In retinal ganglion cells, RhoGEFs of the Vav family seem to be responsible for Rac activation during growth cone collapse, thereby mediating ephrinA1-EphA endocytosis . In contrast, the RacGAP a2-chimaerin appears to have no influence on receptor-ligand endocytosis, as cultured cortical neurons from a-chimaerin À/À mice do not show changes in absolute EphA4 levels, in the degree of EphA4 phosphorylation ( Figure 4D ) or in the amount of EphA4 localized at the plasma membrane (data not shown).
In any case, the a-chimaerin mouse mutants described here show that axon guidance decisions and subsequent neuronal circuit formation require a delicate balance of RhoGTPase activity. That the role of a2-chimaerin in this process is not only intimately related to that of EphA4 but also to that of Ncks is strongly supported by the fact that Nck mutant mice show defects in EphA4 forward signaling that are very similar to those described here (J.P. Fawcett and T. Pawson, personal communication).
EXPERIMENTAL PROCEDURES YTH Assays
YTH screens were performed essentially as described (Betz et al., 1997; Park and Yun, 2001) . A bait vector encoding the LexA DNA-binding domain in frame with the SH2 domain of a2-chimaerin fused to the kinase domain of Src (pLexN-a2-chimaerin-SH2-src-kinase) was used to screen a P8 rat total-brain cDNA library in pVP16-3 (Vojtek et al., 1993) .
Antibodies, cDNA Constructs, and Reagents Details are provided in the Supplemental Data.
Generation of a-Chimaerin
À/À and a-Chimaerin mut/mut Mice Details are provided in the Supplemental Data.
Gait Analysis
Gait analyses on a-chimaerin
, a-chimaerin mut/mut , and WT littermates were conducted according to previously published procedures (Kullander et al., 2001a; Egea et al., 2005) .
Corticospinal Tract Tracing
Tracing of the corticospinal tract with the anterograde tracer biotin dextrane amine was performed according to previously published procedures (Egea et al., 2005) .
Spinal Cord Electrophysiology
The functional output of the locomotor CPG was studied using extracellular electrophysiology on an in vitro preparation of the spinal cord. Neonatal mice at postnatal day P0-P3 were anesthetized with isofluran (Baxter, Sweden) and decapitated. (Kjaerulff and Kiehn, 1996) ; the onset of each burst was determined directly from recordings without rectifying and filtering the signals. The intrasegmental left-right alternations were analyzed in L2 roots, and the intersegmental L2/L5 alternations were analyzed on either the right or left side in each animal. Only traces showing a stable rhythmic activity were analyzed for coordination coupling. Vector points were derived from 15 locomotor cycles with a five cycle interval in between spanning 75 locomotor cycles. Each point represents the endpoint of a vector, the direction given by the mean phase value and the length given by the focus of phase values around the mean. A phase value of 0.5 reflects alternating activity, and 0.0 reflects synchronous activity.
CIN Tracing Experiment
Spinal cords were prepared from neonatal mice at P0-P3. Mice were anesthetized with isofluran (Baxter, Sweden) and decapitated. Mice were pinned down in a dissection tray and eviscerated. The vertebral column was cleaned of adherent tissue and opened ventrally. After the spinal roots were cut, the spinal cord was removed and pinned down. Fluorescent dextran-amines 3000 Da rhodaminedextran-amine (RDA) and 3000 Da fluorescein-dextran-amine (FDA) (Invitrogen, Sweden) were used for retrograde tracing of commissural interneurons (CINs) as described previously (Glover, 1995) . The tracers were dissolved in a small drop of distilled water to allow collection of minute quantities of tracer on the tip of a fine tungsten needle. Two different application protocols were used ( Figures 3G and 3H) . First, intrasegmental tracing with FDA was used to show local projecting commissural interneurons. A sagittal cut was made parallel to the ventral commissure along the entire L2 segment, and FDA tracer was immediately applied. Second, intersegmental tracing with FDA and RDA was used to locate ascending (aCINs), descending (dCINs), and bifurcating commissural interneurons (adCINs). Therefore, thoracic root 13 (T13) and lumbar root 3 (L3) were identified. With a 20 min interval, a small cut was made across the ventral and ventrolateral funiculi immediately caudal to each of these roots. A different tracer was applied into each cut. For both application protocols, excess dye that diffused away from the cut was removed by using a small pipette to avoid contamination of adjacent areas. Preparations were then incubated in a dark box in oxygenated aCSF (pH 7.4) at room temperature for 12-16 hr. Samples were fixed in 4% paraformaldehyde (PFA) in 0.1 M phosphate-buffered saline (PBS) (pH 7.4) and stored dark at 4 C for 1 week. Spinal cords were washed in PBS and embedded in 4% agarose in 13TAE. 60 mm thick transverse sections were cut on a vibratome (Leica), collected on glass slides, and mounted with 2.5% DABCO (Sigma, Sweden) in glycerol containing 0.1 M Tris (pH 8.6). Slides were stored in the dark at -20 C. Sections were viewed in an Olympus BX61WI microscope (Olympus) with separate filters to view RDA and FDA. The application sites were identified and photographs with a 43 objective were taken of all sections of the L2 level (intrasegmental tracing) or between the two application sites (intersegmental tracing). Higher-magnification photographs were taken with a 103 objective using the OptiGrid Grid Scan Confocal Unit (Qioptiq, Rochester USA) and Volocity software (Improvision, Lexington USA).
Primary Cell Culture and Growth Cone Collapse Assay
The preparation of mouse cortical cultures as well as the stimulation of growth cone collapses and their analysis were performed according to previously published procedures (Kullander et al., 2001a; Egea et al., 2005) .
293FT Cell Culture and Cell Transfections
293FT cells (Invitrogen) were cultured in Dulbecco's modified Eagle's medium (DMEM; Invitrogen) supplemented with 10% heat-inactivated fetal calf serum (FCS; PAA Laboratories), MEM nonessential amino acids, penicillin, streptomycin, and G418. For RacGAP assays, cells were plated onto tissue culture dishes coated with poly-L-lysine (Sigma). 293FT cells were transfected with different plasmids using lipofectamine 2000 (Invitrogen).
Cosedimentation and Coimmunoprecipitation Experiments
293FT cells were transfected with the appropriate expression constructs and kept in culture after transfection for 24 hr before the cells were lysed. The cells were harvested on ice with lysis buffer (20 mM Tris/HCl [pH 7.5], 120 mM NaCl, 10% glycerol, 1% triton X-100, complete proteinase inhibitors [Roche], 20 mM NaF, 10 mM Na-pyrophosphate, and 2 mM Na-orthovanadate), the proteins were solubilized by agitating the cell lysates at 4 C for 30 min on a rotating wheel, and the supernatants were cleared by centrifugation at 100,000 3 g (4 C, 1 hr).
The cleared supernatants were used for either cosedimentaion experiments with bacterially expressed GST fusion proteins or incubated with appropriate antibodies for immunoprecipitation experiments. In immunoprecipitation experiments, antibodies prebound to Protein A Sepharose (Amersham Biosciences) or conjugated to agarose were added to the lysates and incubated for 2 hr at 4 C on a rotating wheel.
The beads were then washed three times with washing buffer (lysis buffer, but 0.5% triton X-100), and subjected to SDS-PAGE and western blotting. For cosedimentation assays, recombinant GST fusion proteins were synthesized in E. coli (Guan and Dixon, 1991) , purified on glutathione sepharose (Amersham Bioscience), and used, immobilized on the resin, for cosedimentation assays with proteins expressed in 293FT cells. For this purpose, the cell lysates and 25 nmol of the sepharose bound GST fusion proteins were incubated for 2 hr at 4 C on a rotator, then washed five times with washing buffer, and analyzed by SDS-PAGE and western blotting.
RacGTP Pull-Down Assays
We used the p21 binding domain of Pak1 (aa 67-150) to isolate GTPloaded Rac from transfected fibroblasts (Benard et al., 1999) . For this purpose, 293FT cells were transfected with chimaerin expression constructs in pcDNA-IRES-EGFP, and with pcDNA3-EphA4 WT or pRK5-Nck2-HA. For the expression of the EGFP control, the pcDNA-IRES-EGFP vector was used. 24 hr after transfection, the cells were harvested on ice with 1 ml ice-cold lysis buffer (20 mM Tris [pH 7.5], 150 mM NaCl, 5 mM MgCl 2 , 1 mM DTT, 10% glycerol, 0.5% nonidet P40, 5 mM b-glycerophosphate, 1 mM PMSF, 0.5 mg/ml leupeptin, 1 mg/ml aprotinin). The proteins were then solubilized for 30 min by incubation at 4 C on a rotating wheel, and the supernatants were cleared by centrifugation at 16,000 3 g (4 C, 10 min). For the determination of the total amount of Rac and for monitoring the expression of the transfected constructs, 100 ml of the cleared supernatents were mixed with SDS-PAGE loading buffer, boiled, and analyzed by SDS-PAGE and western blotting. To pull down GTP-loaded Rac, the supernatants were supplemented with 12.5 mg GST-Pak1 fusion protein immobilized on glutathione sepharose, incubated for 1 hr at 4 C on a rotating wheel, and then washed five times with ice-cold lysis buffer using a cooled centrifuge. The beads were boiled in SDS-PAGE loading buffer, separated on 15% SDS-polyacrylamide gels, and transferred to a PVDF membrane for western blot analysis with an anti-Rac antibody. The amount of total Rac in the supernatants and of GTP-loaded Rac bound to GST-Pak1 was determined with an Odyssey image reader (Li-Cor). The RacGTP/total Rac ratio of the EGFP control was set as 100%, and the ratios obtained from the other constructs were expressed as percentages relative to the control.
Supplemental Data
The Supplemental Data for this article can be found online at http:// www.neuron.org/cgi/content/full/55/5/756/DC1/.
